# EDGAR Filing Document

**Accession Number:** 0001937737
**File Stem:** 0001213900-25-126833
**Filing Date:** 2025-12
**Character Count:** 7160
**Document Hash:** 8d6dfe9724e1a5792ae3a4d822e05cef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-126833.hdr.sgml**: 20251231

**ACCESSION NUMBER**: 0001213900-25-126833

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20251231

**DATE AS OF CHANGE**: 20251231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moolec Science SA
- **CENTRAL INDEX KEY:** 0001937737
- **STANDARD INDUSTRIAL CLASSIFICATION:** TEXTILE MILL PRODUCTS [2200]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41586
- **FILM NUMBER:** 251615814

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009
- **BUSINESS PHONE:** 352 26 49 65 65

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of the** 

**Securities Exchange Act of 1934**

**For the month of December 2025**

**Commission File Number: 001-41586**

**MOOLEC SCIENCE SA**

(Exact name of Registrant as Specified in Its Charter)

**89 Nexus Way, Camana Bay**

**Grand Cayman KY1-9009**

**Cayman Islands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

The information contained in this Form 6-K and any exhibits hereto shall be deemed to be incorporated by reference into the Company's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1937737/000121390024080686/ea0214775-s8_moolec.htm) (Registration No. 333-282263).

**EXHIBIT INDEX**

The following exhibits are filed as part of this Form 6-K:

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| 99.1 | [Press Release](ea027138201ex99-1_moolec.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Moolec Science SA | Moolec Science SA |
|  | (registrant) | (registrant) |
| Date: December 31, 2025 | By: | /s/ Alejandro Antalich |
|  | Name: | Alejandro Antalich |
|  | Title: | &nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Moolec Science SA announces the implementation of a share consolidation of its<br> ordinary shares, par value U.S.$0.10 per share (the "Shares")**

Cayman Islands, December 31, 2025 – Moolec Science SA (NASDAQ: MLEC; "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that its board of directors (the "Board") has determined the effective date and the final ratio for the previously approved share consolidation of Moolec's ordinary shares of par value of US$0.10 each (the "Share Consolidation"). The Share Consolidation will become effective as of 8:00 a.m. (Eastern Time) on January 5, 2026 (the "Effective Date"). The final share consolidation ratio is 15-for-1 so that all shareholders holding every 15 ordinary shares of par value of US$0.10 each will hold 1 ordinary share of par value US$1.50 each.

Accordingly, the number of issued and outstanding ordinary shares will be reduced from 10,891,761 Shares to approximately 726,118 Shares on the Effective Date.

No fractional shares will be issued to any shareholder, and in lieu of issuing any such fractional shares, the fractional shares resulting from the Share Consolidation will be rounded up to the nearest whole share. Except for the adjustments that will result from the treatment of fractional shares, the Share Consolidation will not have any dilutive effect on our shareholders.

Upon the opening of the market on January 5, 2026, the new shares resulting from the Share Consolidation will be admitted to trading on Nasdaq Capital Market under CUSIP number G6223S 125.

The Share Consolidation is intended by the Company to regain compliance with a minimum bid price of U.S.$1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).

Continental Stock Transfer & Trust Company, the Company's transfer agent, with its registered office at 1 State Street 30th Floor, New York, NY 10004-1571, is acting as the transfer agent for the Share Consolidation.

**Forward-looking Statements** 

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to effect a share consolidation and regain compliance under the NASDAQ rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this report will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.